Search

Displaying results 2651 - 2660 of 8517 in total
  1. Drug

    Insulin aspart

    go.drugbank.com/drugs/DB01306
    ApprovedInvestigational

    As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin aspart, to lower glucose levels in the blood. … Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic

  2. Drug

    Daclizumab

    go.drugbank.com/drugs/DB00111
    ApprovedInvestigationalWithdrawn

    Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by … Although Zinbryta (daclizumab) was available for patients as needed until 30 April 2018, Biogen and Abbvie announced a voluntary withdrawal of their product Zinbryta (daclizumab) from the global market

  3. Drug

    Fludarabine

    go.drugbank.com/drugs/DB01073
    ApprovedInvestigational

    Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

  4. Drug

    MB07811

    go.drugbank.com/drugs/DB05192
    Investigational

    MB07811, a small molecule that is administered orally, has been extensively studied preclinically and is currently undergoing clinical testing.

  5. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the

  6. Drug

    Magnesium sulfate

    go.drugbank.com/drugs/DB00653
    ApprovedInvestigationalVet approved

    A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia.

  7. Drug

    Maropitant

    go.drugbank.com/drugs/DB11427
    ExperimentalVet approved

    It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats. … Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs.

  8. Drug

    Nisoxetine

    go.drugbank.com/drugs/DB09186
    Experimental

    It was originally investigated as an antidepressant but has no current clinical applications aside from being a research standard SNRI. … It has been used to research obesity and energy balance, and exerts some local analgesia effects.

  9. Drug

    Aldesleukin

    go.drugbank.com/drugs/DB00041
    ApprovedInvestigational

    for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. … This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon

  10. Drug

    Tolrestat

    go.drugbank.com/drugs/DB02383
    ApprovedWithdrawn

    It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death. … Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications.